These findings suggest that while SYPL-1, CEA, and CA19-9 can be valuable in differentiating rPDAC from controls and metastatic from non-metastatic disease, SYPL-1 shows considerable promise as a biomarker for early detection, disease monitoring, and prognosis prediction in rPDAC. Here, CEACAM5 is linked to metastatic neoplasm.